Scribe Therapeutics priced and began trading its CRISPR-focused IPO, raising about $129 million at the high end of its range. The company offered 8.6 million shares at $15 each, according to the deal terms, and started trading on Nasdaq under the ticker SCTX. Shares opened at $25 and finished the day at $21.65, up 44.3%, underscoring investor appetite for platform and late-stage optionality in gene editing. Scribe is developing CRISPR-based therapies targeting cardiovascular and metabolic diseases. The fresh capital supports continued development and milestone progress as the company scales clinical and manufacturing readiness. The listing adds to a steady stream of biotech IPOs, suggesting capital markets are again rewarding gene-editing narratives with early liquidity and strong first-day demand.